Supriya Lifescience
Ticker > Company >

Supriya Lifescience share price

Supriya Lifescience Ltd.

NSE: SUPRIYA BSE: 543434 SECTOR: Pharmaceuticals & Drugs  2.61 L   521   112

651.50
-3.25 (-0.50%)
BSE: 10 Sep 04:01 PM

Price Summary

Today's High

₹ 665

Today's Low

₹ 647.9

52 Week High

₹ 841.7

52 Week Low

₹ 511.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 5243.45 Cr.

Enterprise Value

₹ 5168.5 Cr.

No. of Shares

8.05 Cr.

P/E

29.44

P/B

5.08

Face Value

₹ 2

Div. Yield

0.15 %

Book Value (TTM)

₹  128.17

CASH

₹ 74.96 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

68.3 %

EPS (TTM)

₹  22.13

Sales Growth

23.74%

ROE

15.73 %

ROCE

22.31%

Profit Growth

32.56 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year23.74%
3 Year13.39%
5 Year15.47%

Profit Growth

1 Year32.56%
3 Year-1.22%
5 Year24.75%

ROE%

1 Year15.73%
3 Year21.24%
5 Year36.66%

ROCE %

1 Year22.31%
3 Year28.12%
5 Year38.83%

Debt/Equity

0

Price to Cash Flow

46.28

Interest Cover Ratio

33.1791

CFO/PAT (5 Yr. Avg.)

0.748802836976067

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 68.30 0.00
Mar 2025 68.30 0.00
Dec 2024 68.30 0.00
Sep 2024 68.30 0.00
Jun 2024 68.30 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 16.625 Cr.
  • Company has been maintaining healthy ROE of 21.2423092929279% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.1204945228842% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 33.1791.
  • The Company has been maintaining an effective average operating margins of 31.1848267744753% in the last 5 years.
  • Company’s PEG ratio is 0.904214952211622.
  • The company has an efficient Cash Conversion Cycle of 10.2042 days.
  • Company has a healthy liquidity position with current ratio of 5.0328.
  • The company has a high promoter holding of 68.3%.

 Limitations

  • The company has shown a poor profit growth of -1.22289087810298% for the Past 3 years.
  • The company has shown a poor revenue growth of 13.3912326197026% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 160.63 166.1 185.65 184.11 145.07
Total Expenditure 98.08 101.39 119.7 116.52 93.37
Operating Profit 62.54 64.72 65.95 67.59 51.7
Other Income 2.22 2.52 2.1 2.98 2.67
Interest 0.34 0.43 0.51 0.42 0.51
Depreciation 4.66 4.74 4.96 6.08 6.45
Exceptional Items 0 0 0 0 0
Profit Before Tax 59.78 62.06 62.58 64.06 47.41
Tax 15.13 15.92 15.8 13.68 12.62
Profit After Tax 44.64 46.15 46.78 50.38 34.79
Adjusted EPS (Rs) 5.55 5.73 5.81 6.26 4.32

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 311.64 391.22 530.05 460.94 570.37
Total Expenditure 213.26 218.07 316.06 332.5 394.68
Operating Profit 98.38 173.15 213.98 128.44 175.69
Other Income 11.07 5.01 7.58 9.94 10.96
Interest 6.85 4.08 4.2 3.08 5.15
Depreciation 6.38 6.76 10.12 11.82 15.81
Exceptional Items 0 0 0 0 0
Profit Before Tax 96.23 167.31 207.25 123.49 165.69
Tax 22.82 43.72 55.44 33.63 46.58
Net Profit 73.4 123.59 151.81 89.86 119.11
Adjusted EPS (Rs.) 10.03 16.89 18.86 11.16 14.8

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 14.64 14.64 16.1 16.1 16.1
Total Reserves 134.56 253.95 599.59 683.36 799.27
Borrowings 2.39 0 0 0 0
Other N/C liabilities 29.46 30.86 19.38 25.04 28.98
Current liabilities 155.39 146.02 99.7 95.78 79.57
Total Liabilities 336.43 445.47 734.76 820.28 923.92
Assets
Net Block 97.99 100.04 189.77 261.54 310.13
Capital WIP 40.21 78.79 43.41 67.63 148.83
Intangible WIP 0 0 0 0 0
Investments 0.05 0.05 0.05 25.3 63.8
Loans & Advances 0.18 1.13 3.98 0.93 0.68
Other N/C Assets 0 0 0 0 0
Current Assets 197.99 265.46 497.54 464.89 400.48
Total Assets 336.43 445.47 734.76 820.28 923.92
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 96.23 167.31 207.25 123.49 165.69
Adjustment 10.24 5.39 6.87 4.61 2.4
Changes in Assets & Liabilities 36.6 -66.82 -104.35 -33.82 -17.14
Tax Paid -27.01 -29.99 -60.96 -30.68 -37.65
Operating Cash Flow 116.06 75.89 48.8 63.61 113.31
Investing Cash Flow -24.53 -46.8 -59.82 -123.65 -173.58
Financing Cash Flow -29.23 -14.52 149.65 -10.28 -22.36
Net Cash Flow 62.31 14.57 138.63 -70.32 -82.63

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 68.30 68.30 68.30 68.30 68.30
saloni satish wagh 0.13 0.13 0.13 0.13 0.13
satish waman wagh 67.64 67.64 67.64 67.64 67.64
shivani satish wagh 0.13 0.13 0.13 0.13 0.13
smita satish wagh 0.40 0.40 0.40 0.40 0.40
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 31.70 31.70 31.70 31.70 31.70
aditya birla sun life ins... 3.61 3.02 2.27 1.49 2.11
cohesion mk best ideas su... 1.99 1.99 2.06 2.06 2.13
hornbill orchid india fun... 1.89 1.89 1.89 1.89 1.89
llp - 0.22 0.32 0.25 0.21

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research HDFC Securities

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY23
Concall Q4FY22
Concall Q3FY25
Concall Q3FY24
Concall Q3FY24
Concall Q3FY23
Concall Q3FY22
Concall Q3FY22
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY23
Presentation Q3FY24
Presentation Q3FY22
Presentation Q2FY23
Presentation Q1FY25

Company News

Supriya Lifescience informs about conference call 19 Aug, 4:56 PM Supriya Lifescience - Quaterly Results 13 Aug, 6:00 PM Supriya Lifescience - Quaterly Results 13 Aug, 6:00 PM Supriya Lifescience - Quaterly Results 27 May, 6:09 PM Supriya Lifescience - Quaterly Results 27 May, 6:09 PM Supriya Lifescience - Quaterly Results 27 May, 6:09 PM Supriya Lifescience informs about scrutinizer’s report 24 Apr, 5:27 PM Supriya Lifescience informs about outcome of postal ballot 24 Apr, 5:25 PM Supriya Lifescience informs about board meeting 10 Mar, 12:57 PM Supriya Lifescience informs about retirement of two independent directors 1 Feb, 3:38 PM Supriya Lifescience informs about press release 25 Jan, 12:12 PM Supriya Lifescience - Quaterly Results 24 Jan, 4:24 PM Supriya Lifescience - Quaterly Results 24 Jan, 4:24 PM Supriya Lifescience - Quaterly Results 24 Jan, 4:24 PM Supriya Lifescience informs about change in name of RTA 2 Jan, 2:20 PM Supriya Lifescience informs about analyst meet 19 Dec, 3:20 PM Supriya Lifescience inaugurates Module E Production Block at Lote Parshuram 17 Dec, 6:31 PM Supriya Lifescience informs about analyst meet 17 Dec, 5:24 PM Supriya Lifescience informs about press release 17 Dec, 4:19 PM Supriya Lifescience strengthens position in international markets 9 Dec, 3:12 PM Supriya Lifescience submits analyst meet intimation 7 Nov, 4:40 PM Supriya Lifescience - Quaterly Results 28 Oct, 1:49 PM Supriya Lifescience - Quaterly Results 28 Oct, 1:49 PM Supriya Lifescience - Quaterly Results 28 Oct, 1:49 PM Supriya Lifescience informs about board meeting 21 Oct, 12:44 PM Supriya Lifescience informs about compliance certificate 9 Oct, 1:25 PM Supriya Lifescience informs about outcome of AGM 30 Sep, 5:00 PM Supriya Lifescience informs about analyst meet 11 Sep, 12:16 PM Supriya Lifescience informs about analyst meet 9 Sep, 5:18 PM Supriya Lifescience informs about transcript of earnings call 19 Aug, 12:57 PM Supriya Lifescience’s net profit rises 57% in Q1 10 Aug, 3:12 PM Supriya Lifescience - Quaterly Results 10 Aug, 2:18 PM Supriya Lifescience - Quaterly Results 10 Aug, 2:18 PM Supriya Lifescience - Quaterly Results 10 Aug, 2:18 PM Supriya Lifescience informs about earnings call 5 Aug, 11:50 AM Supriya Lifescience submits analyst meet intimation 7 Jun, 4:45 PM Supriya Lifescience - Quaterly Results 28 May, 6:31 PM Supriya Lifescience - Quaterly Results 28 May, 6:31 PM Supriya Lifescience informs about annual secretarial compliance report 27 May, 3:04 PM Supriya Lifescience informs about disclosure 24 Apr, 2:50 PM Supriya Lifescience submits analyst meet intimation 6 Mar, 5:02 PM Supriya Lifescience informs about conference call 5 Mar, 2:53 PM Supriya Lifescience informs about analyst meet 5 Mar, 10:38 AM Supriya Lifescience informs about disclosure 29 Feb, 10:57 AM Supriya Lifescience informs about analyst meet 23 Feb, 2:48 PM Supriya Lifescience - Quaterly Results 7 Feb, 5:44 PM Supriya Lifescience - Quaterly Results 7 Feb, 5:44 PM Supriya Lifescience - Quaterly Results 7 Feb, 5:44 PM Supriya Lifescience gets GMP certification from ANVISA Brazil 5 Jan, 3:12 PM Supriya Lifescience informs about trading window closure 28 Dec, 12:07 PM

Supriya Lifescience Stock Price Analysis and Quick Research Report. Is Supriya Lifescience an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Supriya Lifescience. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Supriya Lifescience has a PE ratio of 29.5784322143041 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Supriya Lifescience has ROA of 13.6583% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Supriya Lifescience has a Current ratio of 5.0328.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Supriya Lifescience has a ROE of 15.7264%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Supriya Lifescience has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Supriya Lifescience has reported revenue growth of 23.7412% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Supriya Lifescience for the current financial year is 30.803513508775%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Supriya Lifescience is Rs 0.8 and the yield is 0.1535%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Supriya Lifescience is Rs 22.1293. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Supriya Lifescience in Ticker for free. Also, one can get the intrinsic value of Supriya Lifescience by using Valuation Calculators, which are available with a Finology ONE subscription. 

Supriya Lifescience FAQs

Q1. What is Supriya Lifescience share price today?
Ans: The current share price of Supriya Lifescience is Rs 654.55.

Q2. What is the market capitalisation of Supriya Lifescience?
Ans: Supriya Lifescience has a market capitalisation of Rs 5268.001674 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Supriya Lifescience?
Ans: The PE ratio of Supriya Lifescience is 29.5784322143041 and the P/B ratio of Supriya Lifescience is 5.10688131874648, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Supriya Lifescience share?
Ans: The 52-week high share price of Supriya Lifescience is Rs 842, and the 52-week low share price of Supriya Lifescience is Rs 511.4.

Q5. Does Supriya Lifescience pay dividends?
Ans: Currently, Supriya Lifescience pays dividends. Dividend yield of Supriya Lifescience is around 0.1535%.

Q6. What are the face value and book value of Supriya Lifescience shares?
Ans: The face value of Supriya Lifescience shares is Rs 2, while the book value per share of Supriya Lifescience is around Rs 128.1702. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Supriya Lifescience?
Ans: Supriya Lifescience has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Supriya Lifescience?
Ans: The ROE of Supriya Lifescience is 15.7264% and ROCE of Supriya Lifescience is 22.3107%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Supriya Lifescience a good buy for the long term?
Ans: The Supriya Lifescience long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Supriya Lifescience undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Supriya Lifescience appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Supriya Lifescience’s financials?
Ans: You can review Supriya Lifescience’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Supriya Lifescience

Supriya Lifescience Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Supriya Lifescience Ltd. is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality generic drugs. With a strong presence in both domestic and international markets, the company has established itself as a trusted provider of affordable healthcare solutions. Supriya Lifescience offers a wide range of products across various therapeutic categories, including cardiovascular, gastrointestinal, respiratory, and women's health. With a commitment to innovation and customer satisfaction, the company has earned a reputation for delivering superior healthcare products.

Supriya Lifescience Ltd. - Share Price

Supriya Lifescience Ltd.'s share price is an important indicator for investors interested in the company. The share price reflects the market's perception of the company's value and future prospects. It is influenced by various factors, including financial performance, industry trends, and market sentiment. Investors can track the share price through our website's stock analysis page. We provide real-time and historical share price data, along with charts and tools to help investors analyze the stock's performance.

Supriya Lifescience Ltd. - Balance Sheet

The balance sheet of Supriya Lifescience Ltd. provides a snapshot of the company's financial position at a given point in time. It reveals the company's assets, liabilities, and shareholders' equity. The balance sheet helps investors assess the company's liquidity, solvency, and ability to generate returns. Using our pre-built screening tools, investors can analyze Supriya Lifescience's balance sheet and identify key financial ratios and indicators. Additionally, our premium features allow for fair value calculations using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Supriya Lifescience Ltd. - Annual Report

The annual report of Supriya Lifescience Ltd. provides a comprehensive overview of the company's performance, strategy, and future prospects. It contains important information such as financial statements, management's discussion and analysis, corporate governance practices, and sustainability initiatives. As part of our commitment to transparency, we make Supriya Lifescience's annual reports available for download on our website. Investors can access these reports to gain deeper insights into the company's operations and make informed investment decisions.

Supriya Lifescience Ltd. - Dividend

Dividends are an important consideration for long-term stock investors. They represent a portion of a company's earnings that is distributed to its shareholders. Supriya Lifescience Ltd. has a track record of consistently sharing its profits with shareholders through dividends. Investors can stay updated on the company's dividend payouts through our stock analysis page. Additionally, our website provides access to research reports and credit ratings that evaluate Supriya Lifescience's dividend payout history and financial stability.

Supriya Lifescience Ltd. - Quarterly Result

Supriya Lifescience Ltd.'s quarterly results provide investors with insights into the company's financial performance and operational efficiency. By monitoring the quarterly results, investors can track the company's progress, identify trends, and assess its ability to generate sustainable earnings. Our website offers downloadable materials such as con-call transcripts and investor presentations that provide in-depth analysis and commentary on Supriya Lifescience's quarterly results.

Supriya Lifescience Ltd. - Stock Price

Supriya Lifescience Ltd.'s stock price reflects the market's valuation of the company at any given time. It is influenced by various factors such as financial performance, industry trends, market sentiment, and economic conditions. Our stock analysis page provides investors with real-time and historical stock price data, along with interactive price charts. Investors can utilize our pre-built screening tools to analyze Supriya Lifescience's stock price and identify potential investment opportunities.

Supriya Lifescience Ltd. - Price Chart

Analyzing price charts is an essential tool for technical analysis and understanding Supriya Lifescience Ltd.'s stock price movements. Our website offers interactive price charts that allow investors to track historical price data, identify patterns, and determine potential entry or exit points. By using our pre-built screening tools in combination with price charts, investors can gain valuable insights into Supriya Lifescience's stock price behavior.

Supriya Lifescience Ltd. - News

Staying informed about the latest news and developments in Supriya Lifescience Ltd. is crucial for investors. Our stock analysis page provides a dedicated news section that covers relevant industry news, company announcements, regulatory updates, and market insights. Investors can access our website for the most up-to-date news that can impact Supriya Lifescience's stock performance.

Supriya Lifescience Ltd. - Concall Transcripts

Concall transcripts provide a detailed account of Supriya Lifescience Ltd.'s conference call discussions with analysts and investors. These transcripts offer insights into the company's strategy, financial performance, future outlook, and responses to pertinent questions. As part of our commitment to providing comprehensive information, we make these transcripts available for download on our website. Investors can access them to gain a deeper understanding of Supriya Lifescience's operations and investment prospects.

Supriya Lifescience Ltd. - Investor Presentations

Investor presentations are a valuable resource for understanding Supriya Lifescience Ltd.'s business model, growth strategy, and competitive advantages. These presentations often include financial data, operational highlights, and upcoming initiatives. At our website, we provide downloadable investor presentations to provide investors with a comprehensive overview of Supriya Lifescience's investment potential.

Supriya Lifescience Ltd. - Promoters

Promoters play a critical role in shaping the direction and performance of Supriya Lifescience Ltd. Promoters are individuals or entities that have founded or established the company and hold a significant stake in its equity. Understanding the promoters' background, experience, and ownership is crucial for investors evaluating Supriya Lifescience's long-term prospects. Our stock analysis page provides detailed information about Supriya Lifescience's promoters to help investors make informed decisions.

Supriya Lifescience Ltd. - Shareholders

Shareholders are the owners of Supriya Lifescience Ltd. and have a vested interest in the company's growth and profitability. Identifying the major shareholders and their stake in the company provides insights into the ownership structure and potential influence on decision-making. Our website offers information about Supriya Lifescience's major shareholders, allowing investors to gauge the level of institutional and retail investor participation in the company.

Please note that this content is focused on providing stock analysis information and does not include any financial data or numbers about the stock.  

Supriya Lifescience Balance Sheet Overview

Supriya Lifescience's financial standing has shown significant progression from March 2020 to March 2024, according to its balance sheet data. Notably, the total liabilities and assets have grown from Rs. 336.43 Cr. in March 2020 to Rs. 923.92 Cr. in March 2024. This indicates a healthy expansion in the company's operational scale and financial base.

Supriya Lifescience's Growth in Reserves

The total reserves have seen a remarkable increase from Rs. 134.56 Cr. in March 2020 to Rs. 799.27 Cr. in March 2024. This substantial growth in reserves reflects a robust financial reinforcement, enhancing the company's ability to fund future expansions or weather economic downturns.

Supriya Lifescience's Debt Management

The company's financial strategy seems effective as showcased by the reduction in borrowings to zero from Rs. 2.39 Cr. in March 2020. This indicates a strong emphasis on lessening financial risk and improving creditworthiness.

Analysis of Supriya Lifescience's Asset Growth

The asset side of the balance sheet displays a consistent increase, especially in Net Block and Capital WIP, which is pivotal for long-term investment. The Net Block has grown from Rs. 97.99 Cr. in March 2020 to Rs. 310.13 Cr. in March 2024, and the Capital WIP from Rs. 40.21 Cr. to Rs. 148.83 Cr. over the same period.

Supriya Lifescience Current Assets Dynamics

Despite a peak in March 2022 at Rs. 497.54 Cr., current assets stood at Rs. 400.48 Cr. in March 2024, reflecting strategic adjustments in operational asset management.

This data is an analysis for the Standalone Balance Sheet of Supriya Lifescience.

With stock markets fluctuating, investors often look forward to robust balance sheets like that of Supriya Lifescience to gauge stability and growth potential.

Read More
X